PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
15518736-13	2004	Patients who received cyclosporine (CSA), prednisone (Pred), and mycophenolate mofetil (MMF) showed better graft survival than ones on CSA, Pred, and azathioprine (Aza) (P = .18).	Azathioprine	164-167	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	36-39	
16716758-9	2006	Also, 88% of patients already on azathioprine and requiring colectomy underwent surgery within the first year of receiving CSA.	Azathioprine	33-45	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	123-126	
15864171-16	2005	CSA may act as a "bridge" until the therapeutic action of azathioprine is achieved for maintenance treatment.	Azathioprine	58-70	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	0-3	
9825816-8	1998	Median serum creatinine was lower in the Aza group (Aza: 119 micromol/L; CsA.	Azathioprine	41-44	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	73-76	
12352910-10	2002	CONCLUSIONS: Replacement of MMF by AZA after 3 months of therapy with ME-CsA and steroids provides comparable efficacy and safety profiles to continuous MMF over 12 months.	Azathioprine	35-38	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	70-76	
9698512-1	1998	BACKGROUND: Recent multicenter reports have demonstrated improved outcome in recipients of cadaveric renal transplants treated with mycophenolate mofetil (MMF) versus azathioprine (AZA) in combination with cyclosporine A (CSA) and prednisone.	Azathioprine	181-184	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	222-225	
7733148-8	1995	Patients whose immunosuppressive regimen was CsA-based had a 1-year graft survival of 71.5 versus 63.6% in the AZA group.	Azathioprine	111-114	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	45-48	
14621717-10	1992	CSA/AZA is a good immunosuppressive regime for the first renal transplant in children, but only 75% tolerated AZA/CSA without same damage to their grafts.	Azathioprine	110-113	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	0-3	
3278431-7	1988	In the CsA group, 71% required either a significant reduction in CsA dosage with the addition of azathioprine or a complete switch to azathioprine, mainly because of CsA-associated nephrotoxicity.	Azathioprine	97-109	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	7-10	
3278431-7	1988	In the CsA group, 71% required either a significant reduction in CsA dosage with the addition of azathioprine or a complete switch to azathioprine, mainly because of CsA-associated nephrotoxicity.	Azathioprine	134-146	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	7-10	
8794271-1	1995	This single center analysis shows further improvement in the already excellent long-term, cadaveric renal allograft survival with Aza since the introduction of CsA.	Azathioprine	130-133	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	160-163	
7507270-5	1994	The effects of CsA abrogated the effects of AZA when both were present during pregnancy.	Azathioprine	44-47	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	15-18	
7507270-15	1994	This work suggests that the presence of CsA throughout pregnancy has only a minimal effect on fetal immune development and appears to have less impact on T cells than does exposure to AZA only.	Azathioprine	184-187	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	40-43	
3284065-9	1988	On the other hand, a significant (P less than .01) early maturation of blood-borne monocytes into tissue macrophages was observed in the CsA-treated grafts in context of first rejection, which was lacking from those treated with CsA + MP or Aza + MP.	Azathioprine	241-244	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	137-140